Inflammatory Bowel Disease Treatment Market 2028 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

    Inflammatory Bowel Disease Treatment Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Drug Class (Aminosalicyclates, Immunomodulators, TNF Inhibitors, Corticosteroids); Disease Indication (Crohn's Disease, Ulcerative Colitis); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

    Report Code: TIPRE00003491 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET OVERVIEW

    Inflammatory bowel disease (IBD) is a term which is used to describe the disorders that involve chronic inflammation of the digestive tract. The two types of IBD include namely, ulcerative colitis and crohn's disease that usually involve severe diarrhea, abdominal pain, fatigue and weight loss. The treatment of the IBD is to reduce the inflammation that triggers your signs and symptoms. The treatment involve the drug therapy or surgery. Drugs therapy include, Anti-inflammatory drugs that further include corticosteroids and aminosalicylates such as, mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum), depending upon the affected area of colon.

    MARKET SCOPE

    The

    “Global Inflammatory Bowel Disease Treatment Market Analysis to 2028”

    is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of the inflammatory bowel disease treatment market with detailed market segmentation by drug class type, disease indication, distribution channel, and geography. The report provides key statistics on the market status of the leading inflammatory bowel disease treatment market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION

    • Based on drug class type, the market is segmented as, aminosalicyclates, immunomodulators, TNF inhibitors, and corticosteroids.
    • On the basis of disease indication, the market is segmented into crohn's disease and ulcerative colitis
    • Based on the distribution channel, the global inflammatory bowel disease treatment market is classified as, hospital pharmacy, online pharmacy, and retail pharmacy.

    MARKET DYNAMICS

    Drivers:

    • Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD)
    • Rising prevalence of Crohn’s disease and ulcerative colitis

    Restraints:

    • High cost of treatment

    REGIONAL FRAMEWORK

    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The inflammatory bowel disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

    The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the inflammatory bowel disease treatment market in these regions.

    IMPACT OF COVID-19 ON INFLAMMATORY BOWEL DISEASE TREATMENT MARKET

    COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 Pandemic has increased the demand inflammatory bowel disease treatment across the globe.

    Owing to the COVID 19 situation, there were many of the companies focused on the development of the effective vaccines, biologics and drugs to prevent/cure the disease. However, due to the slowdown of development and manufacturing of other pharmaceuticals or biologics coupled with supply chain disruption, the market has witnessed difficulties in 2020. Further, due to the several limitations of the lockdown, cares for children with IBD have been kept to minimal standards, giving priorities to the urgencies and to biologics' infusions and implementing telemedicine services.

    MARKET PLAYERS

    The report covers key developments in the inflammatory bowel disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from inflammatory bowel disease treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for inflammatory bowel disease treatment in the global market.

    The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the inflammatory bowel disease treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    • Pfizer Inc.
    • Novartis AG
    • JOHNSON and JOHNSON (Janssen Global Services, LLC)
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • ALLERGAN
    • CELGENE CORPORATION
    • Bausch Health
    • UCB, Inc.
    • Cosmo Pharmaceuticals NV

    The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Inflammatory Bowel Disease Treatment - By Drug Class
    1.3.2 Inflammatory Bowel Disease Treatment - By Disease Indication
    1.3.3 Inflammatory Bowel Disease Treatment - By Distribution Channel
    1.3.4 Inflammatory Bowel Disease Treatment - By Region
    1.3.4.1 By Country

    2. KEY TAKEWAYS

    3. RESEARCH METHODOLOGY

    4. INFLAMMATORY BOWEL DISEASE TREATMENT LANDSCAPE
    4.1. OVERVIEW
    4.2. PEST ANALYSIS
    4.2.1 North America - Pest Analysis
    4.2.2 Europe - Pest Analysis
    4.2.3 Asia-Pacific - Pest Analysis
    4.2.4 Middle East and Africa - Pest Analysis
    4.2.5 South and Central America - Pest Analysis
    4.3. EXPERT OPINIONS

    5. INFLAMMATORY BOWEL DISEASE TREATMENT - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

    6. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET ANALYSIS
    6.1. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
    6.2. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    7.1. OVERVIEW
    7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    7.3. AMINOSALICYCLATES
    7.3.1. Overview
    7.3.2. Aminosalicyclates Market Forecast and Analysis
    7.4. IMMUNOMODULATORS
    7.4.1. Overview
    7.4.2. Immunomodulators Market Forecast and Analysis
    7.5. TNF INHIBITORS
    7.5.1. Overview
    7.5.2. TNF Inhibitors Market Forecast and Analysis
    7.6. CORTICOSTEROIDS
    7.6.1. Overview
    7.6.2. Corticosteroids Market Forecast and Analysis

    8. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
    8.1. OVERVIEW
    8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
    8.3. CROHN'S DISEASE
    8.3.1. Overview
    8.3.2. Crohn's Disease Market Forecast and Analysis
    8.4. ULCERATIVE COLITIS
    8.4.1. Overview
    8.4.2. Ulcerative Colitis Market Forecast and Analysis

    9. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
    9.1. OVERVIEW
    9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
    9.3. HOSPITAL PHARMACY
    9.3.1. Overview
    9.3.2. Hospital Pharmacy Market Forecast and Analysis
    9.4. ONLINE PHARMACY
    9.4.1. Overview
    9.4.2. Online Pharmacy Market Forecast and Analysis
    9.5. RETAIL PHARMACY
    9.5.1. Overview
    9.5.2. Retail Pharmacy Market Forecast and Analysis

    10. INFLAMMATORY BOWEL DISEASE TREATMENT REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Inflammatory Bowel Disease Treatment Overview
    10.1.2 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis
    10.1.3 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
    10.1.4 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
    10.1.5 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
    10.1.6 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
    10.1.6.1 United States Inflammatory Bowel Disease Treatment
    10.1.6.1.1 United States Inflammatory Bowel Disease Treatment by Drug Class
    10.1.6.1.2 United States Inflammatory Bowel Disease Treatment by Disease Indication
    10.1.6.1.3 United States Inflammatory Bowel Disease Treatment by Distribution Channel
    10.1.6.2 Canada Inflammatory Bowel Disease Treatment
    10.1.6.2.1 Canada Inflammatory Bowel Disease Treatment by Drug Class
    10.1.6.2.2 Canada Inflammatory Bowel Disease Treatment by Disease Indication
    10.1.6.2.3 Canada Inflammatory Bowel Disease Treatment by Distribution Channel
    10.1.6.3 Mexico Inflammatory Bowel Disease Treatment
    10.1.6.3.1 Mexico Inflammatory Bowel Disease Treatment by Drug Class
    10.1.6.3.2 Mexico Inflammatory Bowel Disease Treatment by Disease Indication
    10.1.6.3.3 Mexico Inflammatory Bowel Disease Treatment by Distribution Channel
    10.2. EUROPE
    10.2.1 Europe Inflammatory Bowel Disease Treatment Overview
    10.2.2 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis
    10.2.3 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
    10.2.4 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
    10.2.5 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
    10.2.6 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
    10.2.6.1 Germany Inflammatory Bowel Disease Treatment
    10.2.6.1.1 Germany Inflammatory Bowel Disease Treatment by Drug Class
    10.2.6.1.2 Germany Inflammatory Bowel Disease Treatment by Disease Indication
    10.2.6.1.3 Germany Inflammatory Bowel Disease Treatment by Distribution Channel
    10.2.6.2 France Inflammatory Bowel Disease Treatment
    10.2.6.2.1 France Inflammatory Bowel Disease Treatment by Drug Class
    10.2.6.2.2 France Inflammatory Bowel Disease Treatment by Disease Indication
    10.2.6.2.3 France Inflammatory Bowel Disease Treatment by Distribution Channel
    10.2.6.3 Italy Inflammatory Bowel Disease Treatment
    10.2.6.3.1 Italy Inflammatory Bowel Disease Treatment by Drug Class
    10.2.6.3.2 Italy Inflammatory Bowel Disease Treatment by Disease Indication
    10.2.6.3.3 Italy Inflammatory Bowel Disease Treatment by Distribution Channel
    10.2.6.4 Spain Inflammatory Bowel Disease Treatment
    10.2.6.4.1 Spain Inflammatory Bowel Disease Treatment by Drug Class
    10.2.6.4.2 Spain Inflammatory Bowel Disease Treatment by Disease Indication
    10.2.6.4.3 Spain Inflammatory Bowel Disease Treatment by Distribution Channel
    10.2.6.5 United Kingdom Inflammatory Bowel Disease Treatment
    10.2.6.5.1 United Kingdom Inflammatory Bowel Disease Treatment by Drug Class
    10.2.6.5.2 United Kingdom Inflammatory Bowel Disease Treatment by Disease Indication
    10.2.6.5.3 United Kingdom Inflammatory Bowel Disease Treatment by Distribution Channel
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Inflammatory Bowel Disease Treatment Overview
    10.3.2 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis
    10.3.3 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
    10.3.4 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
    10.3.5 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
    10.3.6 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
    10.3.6.1 Australia Inflammatory Bowel Disease Treatment
    10.3.6.1.1 Australia Inflammatory Bowel Disease Treatment by Drug Class
    10.3.6.1.2 Australia Inflammatory Bowel Disease Treatment by Disease Indication
    10.3.6.1.3 Australia Inflammatory Bowel Disease Treatment by Distribution Channel
    10.3.6.2 China Inflammatory Bowel Disease Treatment
    10.3.6.2.1 China Inflammatory Bowel Disease Treatment by Drug Class
    10.3.6.2.2 China Inflammatory Bowel Disease Treatment by Disease Indication
    10.3.6.2.3 China Inflammatory Bowel Disease Treatment by Distribution Channel
    10.3.6.3 India Inflammatory Bowel Disease Treatment
    10.3.6.3.1 India Inflammatory Bowel Disease Treatment by Drug Class
    10.3.6.3.2 India Inflammatory Bowel Disease Treatment by Disease Indication
    10.3.6.3.3 India Inflammatory Bowel Disease Treatment by Distribution Channel
    10.3.6.4 Japan Inflammatory Bowel Disease Treatment
    10.3.6.4.1 Japan Inflammatory Bowel Disease Treatment by Drug Class
    10.3.6.4.2 Japan Inflammatory Bowel Disease Treatment by Disease Indication
    10.3.6.4.3 Japan Inflammatory Bowel Disease Treatment by Distribution Channel
    10.3.6.5 South Korea Inflammatory Bowel Disease Treatment
    10.3.6.5.1 South Korea Inflammatory Bowel Disease Treatment by Drug Class
    10.3.6.5.2 South Korea Inflammatory Bowel Disease Treatment by Disease Indication
    10.3.6.5.3 South Korea Inflammatory Bowel Disease Treatment by Distribution Channel
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Inflammatory Bowel Disease Treatment Overview
    10.4.2 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis
    10.4.3 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
    10.4.4 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
    10.4.5 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
    10.4.6 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Inflammatory Bowel Disease Treatment
    10.4.6.1.1 South Africa Inflammatory Bowel Disease Treatment by Drug Class
    10.4.6.1.2 South Africa Inflammatory Bowel Disease Treatment by Disease Indication
    10.4.6.1.3 South Africa Inflammatory Bowel Disease Treatment by Distribution Channel
    10.4.6.2 Saudi Arabia Inflammatory Bowel Disease Treatment
    10.4.6.2.1 Saudi Arabia Inflammatory Bowel Disease Treatment by Drug Class
    10.4.6.2.2 Saudi Arabia Inflammatory Bowel Disease Treatment by Disease Indication
    10.4.6.2.3 Saudi Arabia Inflammatory Bowel Disease Treatment by Distribution Channel
    10.4.6.3 U.A.E Inflammatory Bowel Disease Treatment
    10.4.6.3.1 U.A.E Inflammatory Bowel Disease Treatment by Drug Class
    10.4.6.3.2 U.A.E Inflammatory Bowel Disease Treatment by Disease Indication
    10.4.6.3.3 U.A.E Inflammatory Bowel Disease Treatment by Distribution Channel
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Inflammatory Bowel Disease Treatment Overview
    10.5.2 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis
    10.5.3 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
    10.5.4 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
    10.5.5 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
    10.5.6 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Inflammatory Bowel Disease Treatment
    10.5.6.1.1 Brazil Inflammatory Bowel Disease Treatment by Drug Class
    10.5.6.1.2 Brazil Inflammatory Bowel Disease Treatment by Disease Indication
    10.5.6.1.3 Brazil Inflammatory Bowel Disease Treatment by Distribution Channel
    10.5.6.2 Argentina Inflammatory Bowel Disease Treatment
    10.5.6.2.1 Argentina Inflammatory Bowel Disease Treatment by Drug Class
    10.5.6.2.2 Argentina Inflammatory Bowel Disease Treatment by Disease Indication
    10.5.6.2.3 Argentina Inflammatory Bowel Disease Treatment by Distribution Channel

    11. INDUSTRY LANDSCAPE
    11.1. MERGERS AND ACQUISITIONS
    11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    11.3. NEW PRODUCT LAUNCHES
    11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    12. INFLAMMATORY BOWEL DISEASE TREATMENT, KEY COMPANY PROFILES
    12.1. PFIZER INC.
    12.1.1. Key Facts
    12.1.2. Business Description
    12.1.3. Products and Services
    12.1.4. Financial Overview
    12.1.5. SWOT Analysis
    12.1.6. Key Developments
    12.2. NOVARTIS AG
    12.2.1. Key Facts
    12.2.2. Business Description
    12.2.3. Products and Services
    12.2.4. Financial Overview
    12.2.5. SWOT Analysis
    12.2.6. Key Developments
    12.3. JOHNSON AND JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
    12.3.1. Key Facts
    12.3.2. Business Description
    12.3.3. Products and Services
    12.3.4. Financial Overview
    12.3.5. SWOT Analysis
    12.3.6. Key Developments
    12.4. ABBVIE INC.
    12.4.1. Key Facts
    12.4.2. Business Description
    12.4.3. Products and Services
    12.4.4. Financial Overview
    12.4.5. SWOT Analysis
    12.4.6. Key Developments
    12.5. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    12.5.1. Key Facts
    12.5.2. Business Description
    12.5.3. Products and Services
    12.5.4. Financial Overview
    12.5.5. SWOT Analysis
    12.5.6. Key Developments
    12.6. ALLERGAN
    12.6.1. Key Facts
    12.6.2. Business Description
    12.6.3. Products and Services
    12.6.4. Financial Overview
    12.6.5. SWOT Analysis
    12.6.6. Key Developments
    12.7. CELGENE CORPORATION
    12.7.1. Key Facts
    12.7.2. Business Description
    12.7.3. Products and Services
    12.7.4. Financial Overview
    12.7.5. SWOT Analysis
    12.7.6. Key Developments
    12.8. BAUSCH HEALTH
    12.8.1. Key Facts
    12.8.2. Business Description
    12.8.3. Products and Services
    12.8.4. Financial Overview
    12.8.5. SWOT Analysis
    12.8.6. Key Developments
    12.9. UCB, INC.
    12.9.1. Key Facts
    12.9.2. Business Description
    12.9.3. Products and Services
    12.9.4. Financial Overview
    12.9.5. SWOT Analysis
    12.9.6. Key Developments
    12.10. COSMO PHARMACEUTICALS
    12.10.1. Key Facts
    12.10.2. Business Description
    12.10.3. Products and Services
    12.10.4. Financial Overview
    12.10.5. SWOT Analysis
    12.10.6. Key Developments

    13. APPENDIX
    13.1. ABOUT THE INSIGHT PARTNERS
    13.2. GLOSSARY OF TERMS
    The List of Companies

    1. Pfizer Inc.
    2. Novartis AG
    3. JOHNSON & JOHNSON (Janssen Global Services, LLC)
    4. AbbVie Inc.
    5. Takeda Pharmaceutical Company Limited
    6. ALLERGAN
    7. CELGENE CORPORATION
    8. Bausch Health
    9. UCB, Inc.
    10. COSMO PHARMACEUTICALS
    TIPRE00003491
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount